dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Polichronis, A. | en |
dc.contributor.author | Katsohis, C. | en |
dc.contributor.author | Gennatas, Constantinos | en |
dc.contributor.author | Toussis, D. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Vassilaros, S. | en |
dc.contributor.author | Semoglou, C. | en |
dc.contributor.author | Giannakakis, T. | en |
dc.contributor.author | Fahantidis, E. | en |
dc.contributor.author | Klouvas, G. D. | en |
dc.contributor.author | Tsavaris, N. | en |
dc.contributor.author | Konstantaras, C. | en |
dc.contributor.author | Makrantonakis, P. | en |
dc.contributor.author | Kolotas, C. | en |
dc.contributor.author | Zamboglou, N. | en |
dc.contributor.author | Tsiliakos, S. | en |
dc.contributor.author | Hainoglou, D. | en |
dc.contributor.author | Mylonakis, N. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Fountzilas, George | en |
dc.creator | Polichronis, A. | en |
dc.creator | Katsohis, C. | en |
dc.creator | Gennatas, Constantinos | en |
dc.creator | Toussis, D. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Vassilaros, S. | en |
dc.creator | Semoglou, C. | en |
dc.creator | Giannakakis, T. | en |
dc.creator | Fahantidis, E. | en |
dc.creator | Klouvas, G. D. | en |
dc.creator | Tsavaris, N. | en |
dc.creator | Konstantaras, C. | en |
dc.creator | Makrantonakis, P. | en |
dc.creator | Kolotas, C. | en |
dc.creator | Zamboglou, N. | en |
dc.creator | Tsiliakos, S. | en |
dc.creator | Hainoglou, D. | en |
dc.creator | Mylonakis, N. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:06Z | |
dc.date.available | 2018-06-22T09:53:06Z | |
dc.date.issued | 1996 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41664 | |
dc.description.abstract | 362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/ m2), and fluorouracil (500 mg/m2; CNF). After a median follow-up of 51 months, 64 (36%) patients relapsed in the CMF group and 60 (33%) in the CNF group (p = 0.8276). By Cox multivariate analysis, tumor size, menopausal status and number of involved nodes were retained as independently significant variables. Toxicities were remarkably similar in both groups. It appears that after a median follow-up of 51 months there is no significant difference in relapse-free survival between node-positive patients with breast cancer who received either 6 cycles of the conventional CMF or the CNF combination as adjuvant treatment. © 1996 S. Karger AG, Basel. | en |
dc.language.iso | eng | en |
dc.source | Oncology (Switzerland) | en |
dc.subject | Article | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast neoplasms | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Cancer survival | en |
dc.subject | Chemotherapy | en |
dc.subject | Follow up | en |
dc.subject | Priority journal | en |
dc.subject | Tumor volume | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Constipation | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Leukopenia | en |
dc.subject | Multicenter study | en |
dc.subject | Neurotoxicity | en |
dc.subject | Recombinant granulocyte colony stimulating factor | en |
dc.subject | Stomatitis | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Drug fatality | en |
dc.subject | Gastrointestinal toxicity | en |
dc.subject | Randomized controlled trial | en |
dc.subject | Multivariate analysis | en |
dc.subject | Survival rate | en |
dc.subject | Adjuvant | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Heart infarction | en |
dc.subject | Vomiting | en |
dc.subject | Follow-up studies | en |
dc.subject | Breast cancer | en |
dc.subject | Nausea | en |
dc.subject | Adjuvant chemotherapy | en |
dc.subject | Bone marrow toxicity | en |
dc.subject | Gastrointestinal hemorrhage | en |
dc.subject | Oral drug administration | en |
dc.subject | Remission induction | en |
dc.subject | Relapse | en |
dc.subject | Menopause | en |
dc.subject | Drug toxicity | en |
dc.subject | Liver necrosis | en |
dc.subject | Mitoxantrone | en |
dc.subject | Node-positive | en |
dc.title | Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1159/000227550 | |
dc.description.volume | 53 | |
dc.description.issue | 2 | |
dc.description.startingpage | 137 | |
dc.description.endingpage | 146 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |